oricar-017
oricell therapeutics,polaris pharmaceuticals
['mmsm', 'car t', 'polaris']
polaris phase 1 study of oricar-017, which targets gprc5d, in 10 patients. 100% response rate with favorable safety profile. also effective in 5 patients who had previously received a bcma car t. #mmsm #asco22 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.